<- Go Home
Bioventix PLC
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. It also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Market Cap
GBP 148.9M
Volume
5.6K
Cash and Equivalents
GBP 5.1M
EBITDA
GBP 10.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
GBP 12.4M
Profit Margin
90.95%
52 Week High
GBP 45.80
52 Week Low
GBP 22.00
Dividend
5.44%
Price / Book Value
13.19
Price / Earnings
19.24
Price / Tangible Book Value
13.19
Enterprise Value
GBP 143.8M
Enterprise Value / EBITDA
13.57
Operating Income
GBP 10.5M
Return on Equity
69.08%
Return on Assets
50.09
Cash and Short Term Investments
GBP 5.1M
Debt
N/A
Equity
GBP 11.3M
Revenue
GBP 13.7M
Unlevered FCF
GBP 6.3M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium